Landscape Capital Management L.L.C. Has $4.22 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Landscape Capital Management L.L.C. increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 1,834.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 62,998 shares of the medical device company's stock after buying an additional 59,742 shares during the quarter. Landscape Capital Management L.L.C.'s holdings in DexCom were worth $4,223,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Taylor Frigon Capital Management LLC increased its position in shares of DexCom by 51.6% during the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company's stock worth $2,182,000 after acquiring an additional 11,075 shares in the last quarter. Brooktree Capital Management bought a new position in DexCom during the 3rd quarter worth about $683,000. National Pension Service raised its stake in shares of DexCom by 4.1% in the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company's stock valued at $63,671,000 after purchasing an additional 37,363 shares during the period. Intact Investment Management Inc. bought a new stake in shares of DexCom in the third quarter valued at about $650,000. Finally, Waters Parkerson & CO. LLC boosted its position in shares of DexCom by 4.2% during the second quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company's stock worth $30,912,000 after buying an additional 10,892 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

DXCM has been the subject of several research reports. Wells Fargo & Company raised their price target on shares of DexCom from $80.00 to $90.00 and gave the stock an "overweight" rating in a research note on Friday, October 25th. Morgan Stanley lowered their price target on shares of DexCom from $120.00 to $75.00 and set an "equal weight" rating on the stock in a research note on Friday, July 26th. Sanford C. Bernstein lifted their target price on DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a research report on Friday, October 25th. Raymond James lowered their price target on DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a research report on Friday, October 25th. Finally, JPMorgan Chase & Co. increased their price objective on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, DexCom presently has an average rating of "Moderate Buy" and a consensus price target of $104.59.

DexCom Price Performance

DXCM stock opened at $75.24 on Thursday. The company's 50-day moving average price is $70.29 and its two-hundred day moving average price is $90.44. The firm has a market cap of $29.39 billion, a P/E ratio of 45.05, a P/E/G ratio of 2.30 and a beta of 1.17. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 426 shares of the business's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. The trade was a 0.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.30% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.